Clinical Trials

608 enrolled 17 charts

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

203 enrolled 22 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 7 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT03264547 2025-09-29

EMERALD

446 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

355 enrolled

HER2-positive Breast Cancer

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

315 enrolled 11 charts

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 2 FDA

Breast Neoplasms

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

3,270 enrolled 16 charts

Breast Neoplasms

NCT00769379 2025-06-12

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

2,014 enrolled 16 charts

Carcinoma, Intraductal, Noninfiltrating

NCT01526369 2025-05-09

TH V THL

75 enrolled

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

8,381 enrolled 22 charts

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

652 enrolled 50 charts

Breast Neoplasms

NCT02492711 2025-03-17

SOPHIA

624 enrolled 17 charts 3 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

369 enrolled 19 charts

Breast Neoplasms

NCT01084876 2025-02-11

Compare

475 enrolled 25 charts

Breast Neoplasms

NCT02578368 2024-11-12

FLOT5

183 enrolled

Stomach Neoplasms

NCT03013504 2024-11-06

TROIKA

503 enrolled

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

214 enrolled 16 charts

HER2-positive Breast Cancer

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 3 FDA

Breast Neoplasms

NCT03084237 2024-05-17

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

652 enrolled 15 charts

Breast Neoplasms

NCT05629949 2024-04-23

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

474 enrolled

Breast Neoplasms

NCT04629846 2024-04-19

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

517 enrolled

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

1,095 enrolled 46 charts

Breast Neoplasms

NCT03989037 2023-12-27

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

580 enrolled

HER2-positive Early Breast Cancer

NCT06107790 2023-10-30

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

570 enrolled

HER2-positive Breast Cancer

NCT03262935 2023-10-19

TULIP

437 enrolled 17 charts

Breast Neoplasms

NCT02586025 2023-05-22

PEONY

329 enrolled 33 charts

Breast Neoplasms

NCT01875367 2023-04-05

ChangHER-SC

166 enrolled 24 charts

Breast Neoplasms

NCT05301010 2023-02-27

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

128 enrolled

Breast Cancer Metastatic

NCT03433313 2023-01-20

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

807 enrolled

Breast Neoplasms

NCT04109391 2022-10-26

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

338 enrolled 15 charts

Breast Neoplasms

NCT03705429 2022-08-19

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

51 enrolled

Breast Neoplasms

NCT02162667 2022-08-03

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

562 enrolled 15 charts

HER2-positive Carcinoma of Breast

NCT01966471 2022-06-14

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

1,846 enrolled 19 charts

Breast Neoplasms

NCT02472964 2022-02-14

HERiTAge

500 enrolled 9 charts

Breast Neoplasms

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

809 enrolled 14 charts

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

243 enrolled 23 charts

Breast Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

NCT01989676 2021-07-06

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

707 enrolled 20 charts

Breast Neoplasms

NCT00004067 2021-04-29

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

2,130 enrolled

Breast Neoplasms

NCT01566721 2021-04-27

SafeHER

2,577 enrolled 16 charts 2 FDA

Breast Neoplasms

NCT01774786 2020-12-30

JACOB

780 enrolled 24 charts